Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
01 mars 2024 08h30 HE
|
Kinnate Biopharma; Pierre Fabre Laboratories
Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of...
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
16 févr. 2024 08h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has...
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
09 nov. 2023 16h05 HE
|
Kinnate Biopharma
Reported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor...
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
18 sept. 2023 16h10 HE
|
Kinnate Biopharma
Promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational...
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
08 août 2023 16h05 HE
|
Kinnate Biopharma
Received FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023Cash, cash equivalents and investments of...
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
01 juin 2023 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will...
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
11 mai 2023 16h05 HE
|
Kinnate Biopharma
Presented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting Provided update on ongoing exarafenib monotherapy dose...
Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance
17 avr. 2023 14h35 HE
|
Kinnate Biopharma
KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023KIN-8741, a highly selective c-MET...
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
17 avr. 2023 14h30 HE
|
Kinnate Biopharma
Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse eventsBreadth of responses observed across tumor...
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
15 mars 2023 16h05 HE
|
Kinnate Biopharma
Announced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research...